<?xml version='1.0' encoding='utf-8'?>
<document id="31919558"><sentence text="Effects of oral iron and calcium supplement on the pharmacokinetics and pharmacodynamics of molidustat: an oral HIF-PH inhibitor for the treatment of renal anaemia."><entity charOffset="16-20" id="DDI-PubMed.31919558.s1.e0" text="iron" /><entity charOffset="25-32" id="DDI-PubMed.31919558.s1.e1" text="calcium" /><pair ddi="false" e1="DDI-PubMed.31919558.s1.e0" e2="DDI-PubMed.31919558.s1.e0" /><pair ddi="false" e1="DDI-PubMed.31919558.s1.e0" e2="DDI-PubMed.31919558.s1.e1" /></sentence><sentence text="The present studies assessed the drug-drug interaction of molidustat, a hypoxia-inducible factor prolyl hydroxylase inhibitor, with iron and calcium supplements, which are common medications in patients with anaemia due to chronic kidney disease (CKD)"><entity charOffset="132-136" id="DDI-PubMed.31919558.s2.e0" text="iron" /><entity charOffset="141-148" id="DDI-PubMed.31919558.s2.e1" text="calcium" /><pair ddi="false" e1="DDI-PubMed.31919558.s2.e0" e2="DDI-PubMed.31919558.s2.e0" /><pair ddi="false" e1="DDI-PubMed.31919558.s2.e0" e2="DDI-PubMed.31919558.s2.e1" /></sentence><sentence text="" /><sentence text="Forty-two healthy men received molidustat alone (fasted or fed) or combined with oral iron(II) or calcium(II), given immediately before or between 4 h before and 1 h after molidustat in three randomized, open-label, crossover studies (12-15 participants per study)"><entity charOffset="86-92" id="DDI-PubMed.31919558.s4.e0" text="iron" /></sentence><sentence text=" Molidustat AUC and Cmax were assessed as the main pharmacokinetic parameters, and endogenous erythropoietin (EPO) was measured to evaluate pharmacodynamics" /><sentence text="" /><sentence text="Depending on prandial state, concomitant intake of iron(II) reduced molidustat AUC and Cmax by 50-75% and 46-84%, respectively, and EPO AUC(0-24) and Cmax by 31-44% and 36-48%, respectively"><entity charOffset="51-54" id="DDI-PubMed.31919558.s7.e0" text="iron" /></sentence><sentence text=" The influence of iron(II) declined with increasing the time interval to the intake of molidustat, with reductions in molidustat AUC and Cmax of 9% and 10%, respectively, when iron(II) intake occurred 4 h before molidustat"><entity charOffset="18-21" id="DDI-PubMed.31919558.s8.e0" text="iron" /><entity charOffset="176-179" id="DDI-PubMed.31919558.s8.e1" text="iron" /><pair ddi="false" e1="DDI-PubMed.31919558.s8.e0" e2="DDI-PubMed.31919558.s8.e0" /><pair ddi="false" e1="DDI-PubMed.31919558.s8.e0" e2="DDI-PubMed.31919558.s8.e1" /></sentence><sentence text=" Accordingly, effects on endogenous EPO were less pronounced with increased time separation between oral iron(II) and molidustat intake"><entity charOffset="105-108" id="DDI-PubMed.31919558.s9.e0" text="iron" /></sentence><sentence text=" Calcium(II) reduced molidustat AUC and Cmax by 15% and 47%, respectively, without influence on EPO response" /><sentence text=" All treatments were well tolerated" /><sentence text="" /><sentence text="In contrast to concomitant oral intake of calcium, the effect of oral iron supplements on molidustat pharmacokinetics and pharmacodynamics should be considered, and the two agents should be administered with an appropriate time separation"><entity charOffset="42-49" id="DDI-PubMed.31919558.s13.e0" text="calcium" /><entity charOffset="70-74" id="DDI-PubMed.31919558.s13.e1" text="iron" /><pair ddi="false" e1="DDI-PubMed.31919558.s13.e0" e2="DDI-PubMed.31919558.s13.e0" /><pair ddi="false" e1="DDI-PubMed.31919558.s13.e0" e2="DDI-PubMed.31919558.s13.e1" /></sentence><sentence text="" /></document>